Broad-based spike protein stalk-based vaccine platform for SARS-CoV-2 and other coronaviruses

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: Gary R Whittaker
Organization: CORNELL UNIVERSITY
Fiscal Year: 2021
Award: $196,250
Funding agency: National Institute of Allergy and Infectious Diseases

Project Summary/Abstract
We propose to develop a subunit vaccine for SARS-CoV-2, using a structure-based approach targeting
conserved and functionally essential domains in the stalk region of the viral spike protein. We expect our vaccine
platform to be applicable and effective across a wide range of existing and emerging coronaviruses. As our
system is based on expression in E. coli is it expected to be cost–effective, and our stalk-based approach is
specifically designed to cover a range of distinct coronaviruses. However, it is important to note that our vaccine
platform is highly flexible, with the antigen able to be re-engineered rapidly in the face of a novel coronavirus that
may emerge, and for which the vaccine developed in this application is not effective.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><ACE2><Antigenic Determinants><Antigens><Binding Determinants><COVID-19 vaccine><COVID-19 virus><COVID19 vaccine><COVID19 virus><CoV emergence><CoV-2><CoV2><Coronaviridae><Coronavirus><E coli><E. coli><Engineering><Epitopes><Escherichia coli><Goals><HCoV><Human><Immune response><Immunize><Immunological response><Membrane><Mice><Mice Mammals><Modern Man><Murine><Mus><Nature><Proteins><Receptor Protein><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Serology><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Structure><Subunit Vaccines><System><Testing><Transgenic Mice><Vaccination><Vaccine Antigen><Vaccine Design><Vaccines><Vesicle><Viral><Virus><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><base><corona virus><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus emergence><cost effective><design><designing><develop a vaccine><development of a vaccine><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><flexibility><flexible><hCoV19><host response><human CoV><human corona virus><human coronavirus><immune system response><immunogen><immunoresponse><innovate><innovation><innovative><membrane structure><monoclonal antibody production><mouse model><murine model><nCoV><nCoV2><new CoV><new corona virus><new coronavirus><new vaccines><next generation vaccines><novel><novel CoV><novel corona virus><novel coronavirus><novel vaccines><receptor><response><severe acute respiratory syndrome-CoV><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine development><vaccine for novel coronavirus><vaccine formulation><variants of concern>